The QualityStocks Daily Stock List
- Ignite International Brands, Ltd. (BILZF)
- Iota Communications, Inc. (IOTC)
- Sabina Gold & Silver Corp. (SGSVF)
- Tel-Instrument Electronics Corp. (TIKK)
- US Nuclear Corp. (UCLE)
- Nutra Pharma Corp. (NPHC)
- Blox, Inc. (BLXX)
- Sutter Gold Mining, Inc. (SGMNF)
- Integrated Ventures, Inc. (INTV)
- Alternative Investment Corporation (AIKO)
- Cerebain Biotech Corp. (CBBT)
- Protalex, Inc. (PRTX)
- Eco Science Solutions, Inc. (ESSI)
- Empire Petroleum Corp. (EMPR)
Ignite International Brands, Ltd. (BILZF)
OTC Markets, Cash Crop Today, The Cannabis Investor, New Cannabis Ventures, Investor Place, Business Insider, TradingView, GuruFocus, Morningstar, InvestorsHub, Dividend Investor, Stockwatch, Stockhouse, and PR Newswire reported previously on Ignite International Brands, Ltd. (BILZF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.
Ignite International Brands, Ltd. operates in the cannabis industry in the United States and Canada. The Company sells CBD (cannabidiol) oil and vape products as part of a high-end global cannabis brand. Ignite is a $186 million cannabis company co-founded by Mr. Dan Bilzerian, an Internet personality known for his Instagram posts that show off his lavish lifestyle. Ignite International Brands has its head office in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQX.
Ignite International Brands is a vertically integrated company. Mr. Bilzerian takes an active role and is greatly involved in the development of worldwide strategic initiatives. The intention of these strategic initiatives is to establish the Company as an international leader in the cannabis space.
Ignite operates in permissible CBD and cannabis sectors. The Company’s intention is to expand its business. At present, its business includes branding, marketing, licensing, sales and distribution, across the U.S., Canada and into international jurisdictions such as the United Kingdom (UK) and Mexico through taking advantage of numerous product platforms. Ignite is working on expansion via brand leverage, product development, targeted marketing and strategic supply chain partnerships in each of its active and target jurisdictions.
In September, Ignite International Brands announced the appointment of Mr. John Schaefer as Senior Vice President of Operations and Mr. Sam Sarullo as Chief Digital Officer. Mr. Schaefer brings considerable experience, previously serving as the Vice President of Operations at MedMen. Mr. Sarullo previously served as Head of E-Commerce at PacSun and ULTA Beauty, where he was responsible for increasing e-commerce sales, optimizing digital marketing acquisition, and creating a best-in-class website customer experience.
Last week, Ignite International Brands announced that it intends to complete a non-brokered private placement of convertible debenture units for up to C$50 million, issuable in series. The proceeds from the Offering will be used by Ignite for working capital and other general corporate purposes.
Ignite International Brands, Ltd. (BILZF), closed Wednesday's trading session at $1.6991, off by 2.9086%, on 127,542 volume with 254 trades. The average volume for the last 3 months is 423,768 and the stock's 52-week low/high is $0.498059988/$4.00.
Iota Communications, Inc. (IOTC)
Zacks, Wall Street Reporter, Investing.com, Stockhouse, TradingView, InvestorsHub, PR Newswire, Investors Hangout, Market Wire News, Street Insider, Whale Wisdom, Real Investment Advice, Last10k, Wallet Investor, Market Screener, Stockopedia, and Stockwatch reported beforehand on Iota Communications, Inc. (IOTC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Iota Communications, Inc. is a wireless network carrier and software service company based in New Hope, Pennsylvania. It provides Internet of Things (IoT) solutions that optimize energy efficiency, sustainability, and operations for commercial facilities. The Company provides data-driven insights for sustainability enabled by its network connectivity, advanced analytics platform, and software-as-a-service (SaaS) solutions for commercial and industrial markets throughout the U.S. Iota Communications’ shares trade on the OTC Markets’ OTCQB.
Iota also offers important ancillary products and services that facilitate the adoption of its subscription-based services. This includes solar energy, LED lighting, and HVAC implementation services. In essence, Iota Communications uses technology and connectivity to help businesses save money and become more sustainable.
Concerning Analysis, the Company’s BrightAI platform gives an organization the insights and alerts to increase operational visibility and proactively manage their facility. As a result, a company can identify opportunities, improve performance, as well as share insights across teams and organizations. Regarding Optimization, Iota’s platform (combining data and analytics) provides a continuous feedback loop. This optimizes energy efficiency, improves the performance of a firm’s operations, and drives substantial savings for a facility.
Pertaining to Connecting, using its own 800 MHz FCC-licensed spectrum and multi-access gateways, Iota Communications’ network is purpose built for the IoT. It provides superior building penetration, more reliable coverage, and secure data transmission.
Regarding Collecting, easy-to-install wireless sensors, meters and devices unlock valuable data from an organization’s existing infrastructure (Mechanical, Electrical and Environmental). This provides visibility into a company’s facility operations.
Iota Communications announced this past July the closing of the Spectrum Partners Program and simultaneous launch of Iota Spectrum Partners, LP, an Arizona Limited Partnership (Iota Partners), to consolidate exclusive FCC Radio Spectrum Authorizations currently owned and leased by Iota Networks, LLC (Iota Networks), a wholly-owned subsidiary of Iota Communications.
Last month, Iota Communications announced its financial results for the 2019 Fiscal Year ended May 31, 2019. Total Revenue for its Fiscal Year increased to $2,305,144 versus $290,491 for the comparable prior year period. This increase is mainly related to the addition of the former Solbright business. Iota’s Net Loss rose to $56,777,401 from $16,486,146 for the comparable period the year prior. The increase is significantly in connection with one-time goodwill impairment and merger-related costs. Iota Communications’ financing activities netted $25,300,928 in cash to cover its operating loss and finance its growth.
Iota Communications, Inc. (IOTC), closed Wednesday's trading session at $0.36, off by 2.6764%, on 15,120 volume with 10 trades. The average volume for the last 3 months is 83,847 and the stock's 52-week low/high is $0.305000007/$0.860000014.
Sabina Gold & Silver Corp. (SGSVF)
Streetwise Reports, 24hgold, Market Screener, Resource World, The Prospector News, InvestorsHub, TradingView, Seeking Alpha, Nasdaq, Stockhouse, GlobeNewswire, Dividend Investor, Northern Miner, and MarketWatch reported earlier on Sabina Gold & Silver Corp. (SGSVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Sabina Gold & Silver Corp. is an emerging precious metals company listed on the OTC Markets Group’s OTCQX. Its vision is to maximize shareholder value by becoming a premier gold producer via the exploration, development and mining of its precious metals assets in politically safe mining jurisdictions. The Company has district scale, advanced, high grade gold assets in one of the world’s newest, politically stable mining jurisdictions: Nunavut, Canada. Sabina Gold & Silver has its corporate office in Vancouver, British Columbia.
The Company’s mission is to become a major gold producer through the successful phased development of the Back River District in Nunavut. It is focusing on developing an economically viable mine at Back River. The 100 percent-owned Back River Gold Project is a series of gold deposits in banded iron formation. The project is in southwestern Nunavut, about 520 km northeast of Yellowknife, NWT; 50 km southeast of Xstrata Zinc Canada's Hackett River Silver-Zinc Project; and 75 km southwest of Bathurst Inlet.
The Back River Gold Project is advanced, hosts significant NI 43-101 gold resources and reserves and has completed a Feasibility Study and significant permitting milestones. Back River is an 80 km long district. It has highly prospective opportunities for new discoveries and for expansion from existing deposits. Sabina Gold & Silver’s other projects include the Wishbone Greenstone Belt and Hackett River: Hackett River Silver Royalty.
This past August, Sabina Gold & Silver announced the final results from the remaining four drill holes from 2019’s spring drilling program at its Back River Gold Project. Three drill holes targeted the emerging Nuvuyak gold zone; the fourth drill hole targeted a section of the Hook gold structure, just west of the Goose Main deposit. Results from drill hole 19GSE566W2, a wedge hole off earlier announced hole 19GSE56 (July 18, 2019), continue to return numerous high grade values over significant widths within a broadly mineralized envelope of iron formation at Nuvuyak.
During Q2 2019, Sabina Gold & Silver completed drilling of 6,468 meters over 8 holes at three target areas at the Goose property to follow up on the successes from 2018. Drilling at the recent Nuvuyak discovery was centered on continued scoping of size and grade continuity and was successful in identifying broad zones of gold mineralization roughly 50 meters up-plunge of the original discovery area.
Other targets for the spring program included the Llama Extension where drilling confirmed continuity in the gold structure in the gap between the existing underground 43-101 resource and the Llama extension and at Umwelt Vault, where drilling continues to identify a high-grade corridor in the Umwelt underground.
Sabina Gold & Silver Corp. (SGSVF), closed Wednesday's trading session at $1.3892, off by 0.057554%, on 81,063 volume with 95 trades. The average volume for the last 3 months is 292,855 and the stock's 52-week low/high is $0.730000019/$1.72459995.
Tel-Instrument Electronics Corp. (TIKK)
Zacks, Stock Twits, Investing.com, Simply Wall St, Infront Analytics, Market Screener, Investors Hangout, Business Wire, Whale Wisdom, Stockopedia, MarketBeat, Street Insider, and Trading View reported beforehand on Tel-Instrument Electronics Corp. (TIKK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Tel-Instrument Electronics Corp. is the industry leader in developing and producing field-tested, robust avionic flight line and bench test sets for demanding military and commercial customers. The OTCQB-listed Company designs, manufactures, and sells avionics test and measurement solutions. These are for the commercial air transport, general aviation, and government/military aerospace and defense markets in the United States and globally. Established in 1947, Tel-Instrument Electronics is based in East Rutherford, New Jersey.
The Company operates in two segments, Avionics Government and Avionics Commercial. Tel-Instrument Electronics is ISO-9001:2015 quality certified. The Company is compliant to ESD standard ANSI/ESD S20.20 and its products have received CE certification for sales into Europe. Tel-Instrument’s products have led the avionics support equipment industry to higher levels of integration through combining more test functions into a single unit. This reduces customer acquisition, training, and life-cycle support costs.
The Company provides instruments to test, measure, calibrate, and repair a spectrum of airborne navigation and communication equipment. Furthermore, its products include TS-4530A, an identification friend or foe test set; T-47/M5, a dual crypto test set; and AN/ARM-206, an intermediate level TACAN test set.
Additionally, Tel-Instrument Electronics offers AN/USM-708 and AN/USM-719, which are communications/navigation radio frequency avionics flight line testers; TR-220, a test set that provides test capability for traffic and collision avoidance systems (TCAS), distance measuring equipment, and transponders; TR-36, a commercial navigation and communication test set that provides ramp testing; and TR-420, a ramp test set to test the operation of transponders and interrogators.
Tel-Instrument Electronics also provides multifunction ramp test sets under the T-47NC, T-47NH, and T-47G names; TR-100AF, a rugged ramp test used to verify airborne TACAN equipment; and AN/APM-480A, a transponder, interrogator, and TCAS test set.
Recently, Tel-Instrument Electronics reported a Mode 5 test set order of $535k from the U.S. military. This brings bookings to date (as of September 19, 2019) for Q2 to $4.6 million and orders for the last 12 months to $19.4 million.
Mr. Jeffrey O’Hara, Tel-Instrument Electronics’ President and Chief Executive Officer, stated, “Bookings have improved substantially over the last year reflecting a combination of strong U.S. DoD orders as well as growing international demand for our Mode 5 test sets. In the current quarter, we have secured large Mode 5 test set orders from both Canada and Germany. We anticipate continued strong international demand for Mode 5 test sets as we approach the July 1, 2020 deadline for the decertification of Mode 4 IFF.”
Tel-Instrument Electronics Corp. (TIKK), closed Wednesday's trading session at $3.2, off by 1.5385%, on 2,621 volume with 7 trades. The average volume for the last 3 months is 3,166 and the stock's 52-week low/high is $2.20000004/$6.00.
US Nuclear Corp. (UCLE)
StockPulse, Stock News Now, Morningstar, Market Screener, Real Investment Advice, Energy Central News, Investing.com. Seeking Alpha, Stockhouse, TipRanks, Simply Wall St, Stockopedia, GlobeNewswire, and Insider Financial reported previously on US Nuclear Corp. (UCLE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed, US Nuclear Corp. is a leader in radiation detection. The Company develops, manufactures, and sells radiation detection and measuring equipment worldwide. US Nuclear has 100 plus years of experience providing quality Chemical Radiation Detection and Monitoring Instrumentation. The Company is based in Canoga Park, California.
US Nuclear provides measurement instrumentation for the nuclear energy industry and for developing technological processes including Fusion, Thorium and Molten Salt (MSR) reactor technologies domestically and globally. American and International customers include United States Government Agencies, the U.S. Military, Homeland Security, National Laboratories, Universities, Hospitals, nuclear reactor facilities in the U.S., China, Canada, South Korea, Argentina, Russia, as well as others.
Through three operating divisions (Technical Associates (TA)), Overhoff Technology (OTC), and Electronic Control Concepts (ECC), US Nuclear supplies top of the line instrumentation to any industry utilizing radionuclides. These industries include nuclear power plants, national laboratories, government agencies, homeland security, military, and universities and schools. In addition, industries include research companies, hospitals, medical and dental centers, energy companies, weapons facilities, first responders, local governments, and manufacturing plants.
Furthermore, US Nuclear engages in Product Development and works closely with customers to design a system to meet their specifications. The newest product development of the Company is the incorporation of radiation and chemical sensors with drone mounted platforms. US Nuclear’s strategic partnership with FlyCFam UAV provides a complete package to a customer that flies in all-weather, heavy winds, and with a heavy payload. This provides the opportunity to fly many sensors at one time with real-time wireless download.
Due to new advances, US Nuclear drones are now outfitted with a complete CBRN package, chemical, biological, radiation, and nuclear sensing technology. The DroneRAD detects radiation, including radioactive gamma hot-spots or airborne particulates. Moreover, it is outfitted with chemical detectors and bacterial/viral collection filters. End-users for the DroneRAD include first responders, border security, military, homeland defense, NATO military, waste disposal, oil and gas, chemical plants, nuclear power plants, and many more.
Last month, US Nuclear announced its financial results for Q2 ended June 30, 2019. Sales for the three months ended June 30, 2019 were $1,530,523. This represents an increase of $968,995 or 172 percent versus the same period in 2018. Gross Profit was $785,933 versus $287,799 for the same period in 2018. This represents an increase of 173 percent.
Net Loss from Operations was ($466,019). This is because of stock-based compensation as US Nuclear acquires new partnerships, technology, sales and marketing consultants, and other services to facilitate Company growth.
Mr. Robert I. Goldstein, President, Chief Executive Officer, and Chairman of US Nuclear, said, “Leaving out the stock-based compensation, our business operation had a dollar profit of $338,112, which is the main reason for the cash increase of $424,797. The increase in sales revenue can be attributed to strong sales growth of our signature products, including air quality monitors, tritium monitors, and forensic drones.”
US Nuclear Corp. (UCLE), closed Wednesday's trading session at $0.90, up 1.1236%, on 3,893 volume with 4 trades. The average volume for the last 3 months is 14,368 and the stock's 52-week low/high is $0.202000007/$2.8499999.
Nutra Pharma Corp. (NPHC)
Serious Traders, PennyStocks24, StocksToBuyNow, Pumps and Dumps, Winston Small Cap, Streetwise Reports, MyBestStockAlerts, BUYINS.NET, UndiscoveredEquities, Wallstreetlivechat, and Innovative Marketing reported earlier on Nutra Pharma Corp. (NPHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Nutra Pharma Corp. is a biotechnology company listed on the OTC Markets. The Company specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Nutra Pharma is marketing Nyloxin® and Pet Pain-Away™ in the Over-the-Counter (OTC) pain management market. Founded in 2000, Nutra Pharma is based in Coral Springs, Florida.
By way of its subsidiaries, the Company carries out basic drug discovery research and clinical development. The focus of its approach to drug discovery and the development of new therapeutic agents are based on specialized receptor-binding proteins found in nature, particularly those found in snake venom from the cobra.
Nutra Pharma’s leading drug candidates are RPI-78M and RPI-MN. Its MS drug RPI-78M was earlier granted Orphan Status by the Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis. Nutra Pharma’s RPI-MN inhibits the entry of many viruses known to cause severe neurological damage in diseases such as encephalitis and AIDS. RPI-MN is undergoing development initially for the treatment of HIV. RPI-78M is undergoing development for the treatment of multiple sclerosis (MS).
Additionally, Nutra Pharma looks for strategic licensing partnerships to reduce the risks associated with the drug development process. The Company’s holding, ReceptoPharm, is developing technologies to produce drugs for HIV and MS.
Nutra Pharma’s Designer Diagnostics subsidiary engages in the research and development (R&D) of diagnostic test kits designed to be used for the quick identification of infectious diseases. These include Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
Nutra Pharma offers several drug products for sale for pain treatment. One is Nyloxin®, the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The Company has launched Luxury Feet. This is a new version and packaging of its OTC pain drug Nyloxin. Another product is Nyloxin Extra Strength. This is the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Moreover, the Company has its Pet Pain-Away. This is the first OTC product to treat pain in companion animals without side effects. Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, OTC pain reliever.
In September 2018, Nutra Pharma announced that its work with EuroAmerican IP, LLC resulted in a listing of its Nyloxin® product line on the website, www.GoVets.com. GoVets is the online marketplace under the National Veteran Small Business Coalition (NVSBC) to buy from VA-verified Service-Disabled Veteran-Owned Small Businesses (SDVOSBs).
With growing concern regarding consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an alternative, which does not rely on opiates or non-steroidal anti-inflammatory drugs, known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile.
Nutra Pharma Corp. (NPHC), closed Wednesday's trading session at $0.0003, up 50.00%, on 3,149,610 volume with 24 trades. The average volume for the last 3 months is 4,669,148 and the stock's 52-week low/high is $0.000199999/$0.0006.
Blox, Inc. (BLXX)
Stockwatch, OTC Markets Group, Insider Wisdom, SmallCapVoice, Dividend Investor, PennyStocks24, Capital Cube, Investors Hangout, Marketwired, Savvy Trader Resource, and Real Investment Advice reported previously on Blox, Inc. (BLXX), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Blox, Inc.’s vision is to pioneer the development of mining projects through applying green innovation to traditional mining methods and combining renewable energy and technology into the process. The Company’s plan is to become a global leader in the production of “green minerals”. Blox Minerals is a wholly-owned subsidiary of Blox, Inc. Blox is headquartered in Vancouver, British Columbia and the Company lists on the OTC Markets’ OTCQB.
Blox defines “green minerals” as minerals produced using technologies, best practices, and mine processes implemented to lessen the environmental impacts associated with the extraction and processing of metals and minerals. The Company’s plan is to use renewable energy and technology in the production of green minerals with the aim of turning expensive costs into profits through utilizing renewable energy plants to power its varied projects.
A vital aspect of Blox’s mandate is to implement clean energy into the mining process. This is to effectively “green” the mining process and minimize its environmental impact through lower hydrocarbon emissions. Blox’s plan is to build a portfolio of gold and other minerals and produce them in a socially and environmentally friendly way. Its key concession holdings are in Ghana and Guinea, West Africa. Its projects include Pramkese, Osenase, Asamankese, and Mansounia.
The Mansounia Exploration Licence is centered on Latitude 10º 23’ N and Longitude 9º 47’ W in the Kouroussa Prefecture, Kankan Region, in Guinea, West Africa. It encompasses a surface area of 145 square kms. At Mansounia, significantly fresh rock mineralization has been intersected and as of July 2016, remains unexplored. Mansounia is a priority development asset for the Company.
Blox has entered into a Strategic Alliance Agreement with Ashanti Sankofa, Inc. With this Strategic Alliance Agreement, both parties agreed to grant to the other party a right of first refusal to enter into a joint venture (JV) on any of their respective properties and/or projects and that any future acquisition of natural resource properties, which may be acquired by either party that contains, but is not limited to, gold, precious metals, technology metals or diamonds (Natural Resource Properties), the acquiring party will grant to the other party a right of first refusal to participate in a JV on such Natural Resource Property that shall be at the sole discretion of the acquiring party.
Recently, Blox announced that results received from its auger drilling campaign at Mansounia identified five additional targets. This includes doubling the strike of the Mansounia South Prospect to more than 5 km long. Mansounia contains a current JORC Compliant resource of 1.29-million ounces at a pre-feasibility stage. The project is in the highly prospective Siguiri Basin region of Eastern Guinea.
Mr. Trevor Pickett, Chief Executive Officer of Blox, said last month, "I am excited about the new drill targets identified and the extensions of the drill ready targets unveiled by the auger drilling. Anomalies were revealed in every drill line commenced, which is a very positive sign. These results have given us confidence to move forward with our plans to raise capital to complete the current auger program and then plan high quality resource extensional drilling. We are also well advanced towards the submission of our Mining License application for the Mansounia Gold Project."
Blox, Inc. (BLXX), closed Wednesday's trading session at $0.20, up 33.3333%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 2,153 and the stock's 52-week low/high is $0.026/$0.200000002.
Sutter Gold Mining, Inc. (SGMNF)
Penny Stock Hub, Stockhouse, Streetwise Reports, InvestorsHub, 4-Traders, MarketWatch, Investors Hangout, Cardinal Weekly, TradingView and The Northern Miner reported on Sutter Gold Mining, Inc. (SGMNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Sutter Gold Mining, Inc. engages in the exploration of mineral properties. The Company primarily explores for gold deposits. Sutter currently controls a considerable land position of the Mother Lode in California. The Company has advanced work and exploration programs completed on surrounding land holdings. Sutter Gold Mining has its management office in Lakewood, Colorado. It has its mine office in Sutter Creek, California. The Company lists on the OTC Markets Group’s OTCQB.
Sutter Gold Mining has two projects. One is the Lincoln Project situated in Amador County, on the California Mother Lode Gold Belt. The other is the Santa Teresa Project situated in the Northern Baja area of Mexico.
Regarding Mexico and the Santa Teresa Concession, the Company entered into an exclusive option agreement with The Alamo Group in October of 2006 to acquire a 100 percent interest in the Santa Teresa Mineral Concession. Santa Teresa is in the historic El Alamo gold mining district, southeast of Ensenada. The property is positioned contiguous to and on strike with the past-producing Princessa Mine.
Sutter Gold released in 2009 the assay results from the initial 32-hole Phase 1 program. The results included intercepts as high as 21.10 grams per ton or 0.62 ounces of gold per ton across 1.35 meters and 16.68 g/t of gold across 3.1 meters. These results continued to reveal the potential of this underexplored district. In addition, the results confirmed manifold high-grade veins up to 260 meters along strike from the historic Princessa Gold Mine and that all known structures remain open in all directions.
Sutter Gold Mining also holds the rights to the geologically similar, high-grade El Alamo district of northern Baja in Mexico. This is where historic mining to the water table produced mined grades of 30 to 60 g/t gold.
Regarding the Sutter Gold Project, California, the Lincoln and Comet properties are located on a 551-acre block of mining claims and surface rights 45 miles east southeast of Sacramento, California, in the central part of the 121-mile-long Mother Lode gold belt.
Sutter Gold Mining, Inc. (SGMNF), closed Wednesday's trading session at $0.01, up 96.0784%, on 34,060 volume with 6 trades. The average volume for the last 3 months is 1,034 and the stock's 52-week low/high is $0.000000999/$0.01695.
Integrated Ventures, Inc. (INTV)
Promotion Stock Secrets, OTC Markets, Whale Wisdom, The Street, InvestorsHub, Barchart, TradingView, The OTC Reporter, MarketWatch, YCharts, and Investors Hangout reported on Integrated Ventures, Inc. (INTV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Integrated Ventures, Inc. concentrates on operating subsidiaries in the digital currency sector. The Company’s present crypto portfolio includes BitcoLab – cryptocurrency mining and investing. It also includes Nemesis – manufacturing and sales of mining rigs and equipment. The Company previously went by the name EMS Find, Inc. It changed its corporate name to Integrated Ventures, Inc. in July of 2017. Integrated Ventures has its head office in Huntingdon Valley, Pennsylvania.
In addition, Integrated Ventures’ portfolio includes LoanFunder – the financial platform, designed to integrate with a decentralized and encrypted lending ledger. It offers a secure, efficient, verifiable, and permanent way of storing loan related information.
Integrated Ventures has acquired CreditCalc from ITBS, LLC, a high-end loan management and calculation platform. The expectation is that this stock based transaction will expedite the development lifecycle of Integrated Ventures’ blockchain based lending platform - LoanFunder. CreditCalc permits borrowers and lenders to perform complex calculations related to all kinds of loans. Furthermore, CreditCalc provides users access to the custom credit programs and the ability to shop and compare for different kinds of loan products.
Integrated Ventures entered into an Asset Purchase Agreement (APA) with digiMINE, LLC, earlier this year. This APA is to acquire certain cryptocurrency assets, consisting of 150 assorted ASIC miners and related mining equipment and $175,000 in cash, to be used for the purchase of 145 assorted Antminers by Bitmain Technologies. The remaining capital will be used for the build out for the 5,900 sq ft warehouse facility in Marlboro, New Jersey.
Integrated Ventures announced this past May that it executed the APA to acquire the remaining assets of digiMINE consisting of mining rigs, digital currency, and cash. Pursuant to the executed APA, the total consideration for all the assets being acquired comprises 20,000 Restricted Preferred B Shares, to be issued to digiMINE, LLC.
Recently, Integrated Ventures announced that it entered into a Letter Of Intent (LOI) with Secure Hosting, LLC to acquire certain cryptocurrency equipment comprising 199 revenue generating GPU based mining rigs. With this LOI, the aggregate consideration for the Assets being acquired, comprises 39,679 Preferred B restricted shares, being issued to the selling shareholders of the Secure Hosting, LLC.
Integrated Ventures also recently confirmed the signing of a Definitive Asset Purchase Agreement (DAPA) with Secure Hosting to complete the earlier announced acquisition of 182 ETH mining rigs, comprising 114 Fuel 8 GPU RX570; 68 Fuel 8 GPU P102; and 182 Power Source Units.
Integrated Ventures, Inc. (INTV), closed Wednesday's trading session at $0.03632, up 47.2831%, on 2,006,352 volume with 79 trades. The average volume for the last 3 months is 513,972 and the stock's 52-week low/high is $0.023199999/$0.50.
Alternative Investment Corporation (AIKO)
OTC Markets, InvestorsHub, MarketWatch, Stockhouse, Equity Base, 4-Traders, Market Exclusive, Simply Wall St, GuruFocus, Wealth Simple, Wallet Investor, Investopedia, TradingView, Stockopedia, Barchart, Stockscores, and Stockwolf reported on Alternative Investment Corporation (AIKO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Alternative Investment Corporation (AICO) is a real estate development and acquisition organization. The Company’s focus is on properties in the United States and Japan. AICO has developed a signature approach to managing all facets of the development process. This is from property acquisition, financing and design to construction and marketing.
Established in 2007, the Company previously went by the name Paradigm Resource Management Corporation. It changed its name to Alternative Investment Corporation in September of 2015. AICO’s shares trade on the OTC Markets Group’s OTCQB. The Company has its corporate headquarters in New York, New York.
AICO is a full service developer. It has the ability to quickly move any project from site selection, acquisition and financing to construction, leasing, property management and maintenance. AICO chiefly concentrates on distressed real estate assets and/or alternative real estate developments.
The Company’s emphasis is Technological Innovation, Sustainable Design, as well as Adaptive Reuse for contemporary market requirements. Its dedication is to build close relationships with strategic partners, tenants and investors.
The Company’s other businesses include Green Buildings and Technology. Regarding Technology, AICO has invested in technology start-ups, which can be implemented into its development projects.
AICO’s Projects include AICO Plaza. This is in Takarazuka, Japan. AICO Plaza is 5,162.73 square meters. It has 6 residential floors, 4 commercial floors and adjacent parking with 219 parking spaces.
Another of the Company’s projects is Kyoto Plaza. This plaza is in the thousand year capital, Kyoto, the capital city of Kyoto Prefecture in Honshu, Japan. This project is 7280.49373 square feet. The property is 11 floors. This includes a basement level.
Kyoto Plaza is a combination of commercial and residential space. The Plaza offers 4 floors of stores and parking, 5 residential floors, a data center and storage.
AICO also has its Basil and Barns Project. Basil and Barns is on 101 acres of land in Sullivan County. It is two hours north of New York City.
Basil & Barns offers farmhouse villas in an innovative combination of rustic meets upscale resort. Basil & Barns has 30 farmhouse villas. Each of these is 1725 square feet - 2 bed/2 bath. They can convert into 1 bedrooms and studios.
Alternative Investment Corporation (AIKO), closed Wednesday's trading session at $6.00, up 435.7143%, on 17,611 volume with 51 trades. The average volume for the last 3 months is 233 and the stock's 52-week low/high is $0.009999999/$6.90000009.
Cerebain Biotech Corp. (CBBT)
Greenbackers, Viral Stocks, and Wall Street Mover reported on Cerebain Biotech Corp. (CBBT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Cerebain Biotech Corp. centers on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. A development-stage medical device enterprise, the Company formerly went by the name Discount Dental Materials, Inc. It changed its corporate name to Cerebain Biotech Corp. in June 2014.
Cerebain Biotech lists on the OTC Markets’ OTCQB. The Company is based in Costa Mesa, California.
Cerebain Biotech’s technology has allowed for the development of a medical device that can be implanted using a minimally invasive procedure. Upon implantation, through what will most likely be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.
Cerebain’s device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The Company’s patent-pending device is implanted in the omentum. The omentum is a protective layer of skin that protects the abdominal organs.
The design of the device is to stimulate the omentum in patients with Alzheimer’s disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s disease.
Cerebain Biotech will evaluate the effect of omental stimulation at different intervals and levels of stimulation to measure the device’s ability to slow, stop or reverse the progression of Alzheimer’s disease on patients. The Company’s novel device approach is supported by research and patient outcomes.
Cerebain Biotech has signed a Memorandum of Understanding (MOU) with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the MOU is to commence testing of Cerebain’s Medical Device upon completion of development. Moreover, Cerebain has a manufacturing agreement with Sonos Medical, a medical device supplier.
Recently, Cerebain Biotech announced that its intention is to begin the search process to partner with a Contract Research Organization (CRO). The search comes as the Company prepares for clinical trials and the FDA application process in combination with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. Furthermore, in March, Cerebain announced that its strategic partner, Sonos, added key personnel to its staff to facilitate the acceleration in development of the company’s medical device.
Cerebain Biotech Corp. (CBBT), closed Wednesday's trading session at $0.0016, up 45.4545%, on 75,276,088 volume with 278 trades. The average volume for the last 3 months is 33,386,475 and the stock's 52-week low/high is $0.000549999/$0.083999998.
Protalex, Inc. (PRTX)
StreetInsider, Zacks, TopStockAnalysts, and OTCPicks reported on Protalex, Inc. (PRTX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Protalex, Inc. is a clinical-stage Biopharmaceutical Company based in Florham Park, New Jersey. Its emphasis is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA (Rheumatoid Arthritis) and ITP (Immune Thrombocytopenia). The Company’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. Protalex’s shares trade on the OTC Markets Group’s OTCQB.
Rheumatoid arthritis (RA) is an autoimmune disease. RA is a disorder in which the body’s immune system mistakenly attacks the joints. Immune Thrombocytopenia (ITP) is a blood disorder. ITP can result in easy or excessive bleeding and bruising because of the body’s inability to form blood clots.
Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through reducing the immune-mediated destruction of the platelets. Protalex has open IND’s for the treatment of RA and ITP in the United States, and in Europe, an open IMPD for ITP.
Protalex’s PRTX-100 can (at very low concentrations) bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 has been granted Orphan Drug Designation in the United States and in Europe for the treatment of ITP. This status provides commercial exclusivity benefits, tax credits for certain research, potential research grants and a waiver of the New Drug Application user fee in the United States. Currently, it is the subject of clinical studies in the U.S. and Europe.
PRTX-100 is administered as a short intravenous infusion. The following patents have been granted for PRTX-100: U.S. Patent No. 9,370,552 (‘552 patent) is a continuation patent to initial U.S. patent No. 7,211,258 (Protein A compositions and methods of use) filed in 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE). The ‘552 patent expands the method of treatment of PRTX-100 to include type 1 diabetes.
European Patents No. 2,570,136 and 2,206,511 (national patents in place in France, Germany, Italy, Spain, Switzerland, and the UK) includes composition claims relating to numerous autoimmune diseases (RA, ITP, juvenile RA, psoriasis, myasthenia gravis) and dosage expansion.
Canadian patents No. 2,894,098 and No. 2,481,282 comprise method of treatment claims relating to RA and SLE. Japanese patent No. 5,523,796 claims compositions for treating psoriasis, scleroderma, Crohn’s Disease, myasthenia gravis, ulcerative colitis, psoriatic arthritis, as well as pemphigus vulgaris.
Recently, Protalex announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), it initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.
The first patient in the final cohort was recently dosed in the United Kingdom at 24 micrograms/kg. This the highest dose of PRTX-100 used in any clinical trial to date. One of the three patients treated in the fourth dose cohort (18 micrograms/kg) attained a protocol defined platelet response.
Protalex, Inc. (PRTX), closed Wednesday's trading session at $0.015, up 36.3636%, on 5,000 volume with 3 trades. The average volume for the last 3 months is 4,538 and the stock's 52-week low/high is $0.000199999/$0.224999994.
Eco Science Solutions, Inc. (ESSI)
Wall Street Mover, ThePUMPTracker, DSR News, Real Pennies, Promotion Stock Secrets, TopPennyStockMovers, Wallstreetlivechat, and Pumps and Dumps reported earlier on Eco Science Solutions, Inc. (ESSI), and we also report on the Company, here at the QualityStocks Daily Newsletter.
Eco Science Solutions, Inc. is an eco-technology Company with its corporate headquarters in Makawao, Hawaii. It provides solutions to the multi-billion-dollar health, wellness, and alternative medicine industry. Eco Science Solutions develops technical solutions - from enterprise software solutions, to consumer applications (apps) for daily use. These solutions energize enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science Solutions’ shares trade on the OTC Markets Group’s OTCQB.
Eco Science Solutions’ key services cover localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and fast delivery of products. These all cater to the health-and-wellness lifestyle.
The Company’s brands include Herbo, Fitrix, and pHion Balance. The Herbo app assists consumers in finding products and services that support the intake of alternative medicines for a more naturopathic lifestyle. Herbo has a database of greater than 14,000 alternative medicine locations and delivery services, doctors who provide evaluations, and local shops that sell relevant product.
The Fitrix app is a strong and flexible companion. Fitrix assists users’ in keeping track of their day-to-day fitness routines, dietary habits, and alternative medicine intake. Fitrix users can measure and track anything and everything concerning their health and wellness.
The Company’s pHion Balance underwent development to create nutritional supplements, which support and promote a healthy lifestyle. pHion Balance is centered on developing nutritional supplements that take the guesswork out of supplementing the body in the healthiest way.
Eco Science Solutions will continue to make investments in e-commerce and mobile applications that facilitate B2C (Business-to-Consumer) e-commerce opportunities.
Last year, Eco Science Solutions' main projects focused on continued consumer and enterprise technology investment; continued product formulation and inventory build for distribution; and strategic acquisitions, which provide an accelerated time-frame to obtain market share.
In May of 2017, the Company announced that it signed a Sponsorship, Content Development, and Licensing agreement with Roaring Lion Tours, Inc. Roaring Lion Tours develops inspirational and educational content that further promotes what it believes are the benefits of medical marijuana. This agreement is to develop unique educational content that brings awareness and education to the alternative medicine category.
Eco Science Solutions, Inc. (ESSI), closed Wednesday's trading session at $0.01, up 25.00%, on 10,128 volume with 3 trades. The average volume for the last 3 months is 7,249 and the stock's 52-week low/high is $0.000009999/$0.360000014.
Empire Petroleum Corp. (EMPR)
Nebula Stocks, OTC Markets, and The Street reported previously on Empire Petroleum Corp. (EMPR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Empire Petroleum Corp. engages in the exploration and development of oil and gas interests in North America. The Company owns interest in the Gabbs Valley prospect and interest in the South Okie prospect. The Gabbs Valley prospect is an area of roughly 34,186 gross acres in Nye and Mineral Counties, Nevada. The South Okie prospect encompasses 110 net acres of oil and gas leases in Natrona County, Wyoming. Established in 1983, Empire Petroleum has its corporate headquarters in Tulsa, Oklahoma.
The Company has conducted comprehensive geological studies, conducted a seismic survey, carried out a geochemical imaging survey, conducted satellite and gravity studies and drilled two test wells on the Gabbs Valley Prospect. The additional studies of such data and the assistance of geological and engineering consultants led Empire Petroleum to conclude that additional drilling was warranted. The determination was that a new test well should be drilled employing a different method of drilling.
Empire Petroleum drilled the Paradise Unit 2-12 well to a depth of 4,250 feet before drilling problems caused them to stop drilling. The Company assigned the lease and the 1-12 and 2-12 wells to the other leasehold owners from which Empire had taken a farmout. Empire Petroleum does feel the prospect has considerable geological merit since the main target, being the Triassic formation, was not reached in either of the two test wells.
Empire Petroleum and Sierra Nevada Oil, LLC concentrated their activities on the exploration and development of approximately 36,750 acres of Bureau of Land Management (BLM) leases positioned on a surface anticline in Gabbs, Nevada. Three exploratory wells were drilled on the leases.
In December 2016, Empire Petroleum announced that it entered into an Agreement (Contribution Agreement) with Masterson West, LLC, concerning a newly-formed entity, Masterson West II, LLC (MWII). Upon closing, Empire Petroleum will own up to a maximum of 50 percent of MWII if it delivers $18,000,000 with a proportionate decrease down to 25 percent of Masterson West II at the lower end of the range.
The oil and gas properties are in Moore and Potter Counties in the Texas Panhandle. The wells to be included in the transaction primarily target the Red Cave formation.
In September 2017, Empire Petroleum announced that it entered into a term sheet to acquire producing oil and gas assets in North Louisiana. The oil and gas properties are the East Haynesville and Oaks Fields in Claiborne Parish, Louisiana. The wells to be included in the transaction target the Pettit, Lower and Upper Haynesville, Cotton Valley and Smackover reservoirs.
Recently, Empire Petroleum announced that its Board of Directors retained Pritchard Griffin Advisors (PGA) to advise Empire on its potential NW Louisiana transaction and on other prospective mergers, joint ventures (JVs), and acquisitions for the Company.
Mr. Mike Morrisett, President of Empire Petroleum Corporation, said, “We are very pleased to have PGA engaged with the Company. Their breadth of experience, knowledge, and contacts in most of the major oil and gas basins in the U.S., specifically within the East Texas/Louisiana Cotton Valley/Haynesville play, provides the Company with the confidence to implement our initial strategy within this region.”
Empire Petroleum Corp. (EMPR), closed Wednesday's trading session at $0.199, up 32.6667%, on 1,000 volume with 2 trades. The average volume for the last 3 months is 4,464 and the stock's 52-week low/high is $0.100000001/$0.75.
The QualityStocks Company Corner
- Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)
- Earth Science Tech, Inc. (ETST)
- ChineseInvestors.com (CIIX)
- Cannabis Strategic Ventures, Inc. (NUGS)
- Marijuana Company of America (OTCQB: MCOA)
- Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)
- The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)
- Genprex Inc. (NASDAQ: GNPX)
- Predictive Oncology (NASDAQ: POAI)
- VPR Brands, LP (VPRB)
- Spectrum Global Solutions, Inc. (SGSI)
- SinglePoint, Inc. (SING)
- Neutra Corp. (OTCQB: NTRR)
- Endonovo Therapeutics Inc. (ENDV)
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://cnw.fm/uNpb6) (http://cnw.fm/s1Ue7). Also today, the company was featured in the 420 with CNW by CannabisNewsWire. To mitigate the risks linked with vaping products purchased from the illicit markets, hundreds of leaders in the cannabis industry have signed a the letter for the descheduling of marijuana by Congress.
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.
Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.
Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.
In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.
Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.
Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.
Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.
Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.
Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.53, up 1.9231%, on 66,802 volume with 55 trades. The average volume for the last 3 months is 85,387 and the stock's 52-week low/high is $0.399800002/$1.99.
- Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal
- 420 with CNW – Nearly a Thousand Businesses Sign Letter Asking Congress to Deschedule Marijuana
- Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (ETST) was featured today in a publication from CBDWire, examining how CBD is all the rage these days. It comes with such a wide range of medical benefits that its popularity was only inevitable. Sellers have also picked a lot of interest in this industry with a product this good, and now some of them are looking for ways to beat their competition and come out on top. Also today, CannabisNewsWire released a report on the company detailing how
Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.
Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:
- Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
- Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
- KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.
In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.
The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.
Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.
Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.
The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.
Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.
Earth Science Tech, Inc. (ETST), closed Wednesday's trading session at $0.34, up 6.25%, on 35,124 volume with 24 trades. The average volume for the last 3 months is 45,918 and the stock's 52-week low/high is $0.300999999/$1.95000004.
- CBD Manufacturers Use the Absence of a Notorious Weedkiller to One-Up the Competition
- Earth Science Tech Inc. (ETST) Establishes New CBD Sales Division Concentrating on Therapeutic, Pharmaceutical-Grade Products
- Earth Science Tech Inc.’s (ETST) Hygee Home Kit Playing Key Role in Fight Against STIs and Undiagnosed Cases
ChineseInvestors.com (CIIX) was featured today in a publication from CBDWire, examining how a number of CBD manufacturers, including RE Botanicals and Bluebird Botanicals, have started rolling out CBD products whose labels state the absence of glyphosate to get a little edge over their competitors.
Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.
At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.
CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.
The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.
Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.
In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.
ChineseInvestors.com (CIIX), closed Wednesday's trading session at $0.2678, up 1.8251%, on 46,019 volume with 20 trades. The average volume for the last 3 months is 45,553 and the stock's 52-week low/high is $0.25/$1.04999995.
- CBD Manufacturers Use the Absence of a Notorious Weedkiller to One-Up the Competition
- ChineseInvestors.com Inc. (CIIX) Positioned as First Company to Market CBD Products to Chinese-Speaking Consumers
- CBD Legality Uncertain as Missouri AG Remains Silent
Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)
Cannabis Strategic Ventures Inc. (OTC: NUGS) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled “Californian Cannabis Industry Blazes Trail of Growth for US,” visit: http://cnw.fm/cVQ8B.
Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.
The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.
Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.
Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.
Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.
Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.
Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.
The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.
Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed Wednesday's trading session at $0.165, up 18.705%, on 256,909 volume with 76 trades. The average volume for the last 3 months is 110,752 and the stock's 52-week low/high is $0.125/$4.05000019.
- Cannabis Strategic Ventures Featured in Publication Discussing California’s Lead in Hemp Industry
- Californian Cannabis Industry Blazes Trail of Growth for US
- 420 with CNW – FBI Data Shows Cannabis Arrests Increased Last Year
Marijuana Company of America Inc. (MCOA)
Marijuana Company of America (OTCQB: MCOA) was featured today in the 420 with CNW by CannabisNewsWire. To mitigate the risks linked with vaping products purchased from the illicit markets, hundreds of leaders in the cannabis industry have signed a the letter for the descheduling of marijuana by Congress. The letter is to be delivered on Thursday to the House and Senate leadership.
Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.
The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.
The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.
The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.
Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.
Marijuana Company of America Inc. (MCOA), closed Wednesday's trading session at $0.1583, up 5.463%, on 128,079 volume with 115 trades. The average volume for the last 3 months is 190,379 and the stock's 52-week low/high is $0.023/$2.10599994.
- 420 with CNW – Nearly a Thousand Businesses Sign Letter Asking Congress to Deschedule Marijuana
- Global CBD Prices Reduce as US Supply Shakes the Market
- 420 with CNW – Benefits of Marijuana to People with Traumatic Brain Injury
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) was featured today in a publication from HempWireNews, examining how the 2019 growing season has been full of challenges for hemp growers in the Mid-Atlantic States as they are used to drier climate during the harvesting season; however, this season, spring was soggy, and summer was humid.
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.
Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.
The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.
The company currently has two products on the market and another in the research and development phase:
InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.
InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.
The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.
Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.
A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.
Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.
**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.
Therma Bright, Inc. (OTC: THRBF), closed Wednesday's trading session at $0.022, even for the day, on 10,000 volume. The average volume for the last 3 months is 151 and the stock's 52-week low/high is $0.009899999/$0.028999999.
- Two-Thirds of Pennsylvania Hemp Farmers Don’t Have Purchase Contracts
- Australian Trial Shows CBD Gel Reduces Seizures in Epileptic Kids
- Processing Challenges Could Cause Billions in Losses as Hemp Rots on Farms
The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)
The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, announces that it is reviewing financing alternatives in order to complete construction at its facilities in Ancaster, Ontario and Phase 1a at Valleyfield, Quebec. As previously disclosed, the Company had been engaged in discussions for ordinary course commercial bank facilities and equipment leasing. Also today, the company was featured today in a publication from HempWireNews, examining how the 2019 growing season has been full of challenges for hemp growers in the Mid-Atlantic States as they are used to drier climate during the harvesting season; however, this season, spring was soggy, and summer was humid.
The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).
Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.
TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.
Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.
Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.
The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.
The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.
TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.
Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.
Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.
TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.
To learn more about the company and how to invest, contact TGOD directly at email@example.com
The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $1.065, off by 19.2876%, on 5,969,774 volume with 3,031 trades. The average volume for the last 3 months is 733,501 and the stock's 52-week low/high is $0.990100026/$5.0999999.
- The Green Organic Dutchman Provides Update on Credit Financing
- Two-Thirds of Pennsylvania Hemp Farmers Don’t Have Purchase Contracts
- 420 with CNW – Another Marijuana Legalization Bill Introduced in Mexico Legislature
Genprex Inc. (NASDAQ: GNPX)
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin - Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, October 15 at 9:10 a.m. Central Time, led by its Chairman and CEO Rodney Varner, who will also be available for one-on-one meetings with investors. To view the full press release, visit http://nnw.fm/sISn1.
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Research and Development
Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.
Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.
Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.
TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.
Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.
Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.
Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.
Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.
Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.
Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $0.625, off by 6.8554%, on 43,123 volume with 60 trades. The average volume for the last 3 months is 48,818 and the stock's 52-week low/high is $0.569999992/$2.25999999.
- Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference
- Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
- Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers
Predictive Oncology (NASDAQ: POAI)
In a significant announcement that bodes well for the company, Predictive Oncology Inc. (NASDAQ: POAI)announced that its Skyline Medical Division, producer of the STREAMWAY(R) System, has completed the sale of 10 systems to a major New York hospital (http://nnw.fm/B7hxg). The sale exceeds POAI’s largest single-hospital sale to date, and it is anticipated that the systems collectively will handle 6,000 procedures every year.
Predictive Oncology (POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.
Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.
In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.
TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.
Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.
The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.
Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.
Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.
CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.
Predictive Oncology (POAI), closed Wednesday's trading session at $0.46, off by 2.1277%, on 43,796 volume with 119 trades. The average volume for the last 3 months is 60,396 and the stock's 52-week low/high is $0.419999986/$0.850000023.
- Predictive Oncology Inc. (NASDAQ: POAI) Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System
- Predictive Oncology Inc. (NASDAQ: POAI) Continues to Innovate to Improve Outcomes for Cancer Patients
- Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
VPR Brands, LP (VPRB)
VPR Brands (OTCQB: VPRB), a multivertical, tiered technology holding company in the cannabis space, is set to benefit as demand grows for e-cigarettes and vaping technologies. Internationally, the e-cigarette and vaping market was forecasted in 2018 to reach $10.3 billion and expand at a CAGR of 24.9% through 2025 (http://cnw.fm/7fkPJ). To view the full article, visit http://cnw.fm/cd96V.
Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.
VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:
- GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
- HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
- Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
- Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
- Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
- GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
- Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.
CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.
Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.
VPR Brands, LP (VPRB), closed Wednesday's trading session at $0.0411, off by 8.6667%, on 24,433 volume with 4 trades. The average volume for the last 3 months is 141,113 and the stock's 52-week low/high is $0.033799998/$0.119999997.
- VPR Brands LP (VPRB) Considers Intellectual Property Licensing as Auto-Draw Technology Popularity Rises
- VPR Brands LP (VPRB) Offers Robust Suite of Products in Nicotine, CBD Verticals
- 420 with CNW – Marijuana Legalization Bill Introduced in Pennsylvania
Spectrum Global Solutions, Inc. (SGSI)
Spectrum Global Solutions (OTCQB: SGSI), a leading single-source provider of next-generation communications network infrastructure and maintenance solutions, is poised to profit from the upcoming rollout of 5G anticipated to take place in 2019. To view the full article, visit http://nnw.fm/RVvQ3.
Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:
- AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
- ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
- Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.
Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.
Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.
CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.
Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.
Spectrum Global Solutions, Inc. (SGSI), closed Wednesday's trading session at $0.03, off by 5.3508%, on 31,234 volume with 8 trades. The average volume for the last 3 months is 170,684 and the stock's 52-week low/high is $0.014999999/$1.00999999.
- Spectrum Global Solutions Inc. (SGSI) Positioned to Capitalize on Upcoming 5G Rollout
- Spectrum Global Solutions, Inc. (SGSI) Secures $3.3 Million in New Contract Awards
- Spectrum Global Solutions Inc. (SGSI) Subsidiary Secures Key Contract with Tier-1 Telecommunications Infrastructure Aggregator
SinglePoint, Inc. (SING)
Technology and investment company SinglePoint (OTCQB: SING) today announced major success at the 2019 National Association of Convenience Stores show (“NACS”) in Atlanta. SinglePoint, as the master distributor of Pure American Hemp(TM) Cigarettes, sold multiple cases to retail store owners representing approximately 2500 stores during the show. In addition, SinglePoint was able to directly interact with interested store owners, national distributors and buying groups, accounting for well over 20,000 retail locations and, this week, has ordered additional product to meet demand. To view the full press release, visit http://cnw.fm/8iPrZ.
SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.
SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.
SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:
- A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
- A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
- A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
- Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
- Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
- Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.
SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.
Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.
SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.
SinglePoint, Inc. (SING), closed Wednesday's trading session at $0.01088, off by 0.183486%, on 2,663,392 volume with 97 trades. The average volume for the last 3 months is 2,982,997 and the stock's 52-week low/high is $0.009999999/$0.035999998.
- SinglePoint, Inc. (SING) Lights Up NACS with Launch of Pure American Hemp(TM) Cigarettes
- Australian Trial Shows CBD Gel Reduces Seizures in Epileptic Kids
- SinglePoint, Inc. (SING) CEO Reports from NACS Tradeshow on MoneyTV with Donald Baillargeon
Neutra Corp. (OTCQB: NTRR)
Healthy living solutions research and development company Neutra Corp (OTCQB: NTRR)is preparing for the market release of a new transdermal, hemp-based sports cream designed to provide pain relief for amateur athletes and others involved in activities that require strenuous performance.
Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.
Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.
Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.
- VIVIS – Neutra continues to expand its market presence in the rapidly growing hemp-derived CBD market and recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With VIVIS as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
- J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.
- Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
- ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.
Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.
Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.
Neutra Corp. (OTCQB: NTRR), closed Wednesday's trading session at $0.0007, off by 12.50%, on 6,869,355 volume with 30 trades. The average volume for the last 3 months is 24,352,222 and the stock's 52-week low/high is $0.0006/$0.0898.
- Neutra Corp. (NTRR) Prepares to Introduce CBD-Based Pain Relief for Athletes
- California Cities and Counties Still Divided on Hemp Cultivation
- Neutra Corp. (NTRR) Subsidiary Nearing Market Release of Hemp-Based Sports Cream Expected to be Hit with Amateur and Pro Athletes
Endonovo Therapeutics Inc. (ENDV)
Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.
In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.
SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?
Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.
Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.
Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.
Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?
Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.
Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.
Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.
David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.
Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.
Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.0105, up 1.9417%, on 3,539,102 volume with 52 trades. The average volume for the last 3 months is 4,825,249 and the stock's 52-week low/high is $0.006/$0.0535.
- Endonovo Therapeutics Inc. (ENDV) Appoints Recognized Medical Professional and Business Visionary Dr. William Li as Strategic Advisor to the CEO
- Endonovo Therapeutics Inc. (ENDV) Receives Glowing Video Review on Revolutionary Medical Device
- Endonovo Therapeutics Inc. (ENDV) Developing Solutions to Meet Major Therapeutic Needs
The QualityStocks Numbers Report
QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.
The QualityStocks Sponsored News
- B2Digital Inc. (BTDG) B2 Social Media Network Surpasses 3.9M Connections in Q2 2019
- Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Opens Learning Center Featuring Augmented Reality Games, Educational Content
- Cannabis Strategic Ventures, Inc. (OTCQB: NUGS) Californian Cannabis Industry Blazes Trail of Growth for US
- Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) View from the C-Suite: Narbé Alexandrian, President & Chief Executive Officer, Canopy Rivers Inc., tells his company's story. Filmed on September 24, 2019
- Chemistree Technology Inc. (CSE: CHM) (OTCQB: CHMJF) Announces Cancellation of PCCBD Investment
- ChineseInvestors.com (CIIX) Positioned as First Company to Market CBD Products to Chinese-Speaking Consumers
- Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF) to Acquire 19.9% Equity Interest of Coastal Green, a BC-Based Cannabis Retailer
- City View Green (CSE: CVGR) (OTCQB: LRZZF) Names New CFO; Announces Private Placement, Equity Issuances
- CloudCommerce (OTCQB: CLWD) Positioned as Premier Solution Provider for Business Marketing Sector
- Consorteum Holdings, Inc. (CSRH) Universal Mobile Interface Platform Enables Communication Between Different Platforms and Devices
- Earth Science Tech, Inc. (ETST) Hygee Home Kit Playing Key Role in Fight Against STIs and Undiagnosed Cases
- Endonovo Therapeutics (OTCQB: ENDV) Appoints Recognized Medical Professional and Business Visionary Dr. William Li as Strategic Advisor to the CEO
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Enters Strategic Agreement with Leading Chinese Infrared Camera Manufacturer
- Genprex, Inc. (NASDAQ: GNPX) Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
- Geyser Brands Inc. (TSX.V: GYSR) University of Wyoming Releases Hemp Publication
- GP Solutions (GWPD) Trading to Recommence October 17, 2019
- Grapefruit Boulevard Investments Inc. (IGNG) 420 with CNW – Cannabis Expo in West Michigan Set to Educate Consumers and Businesses about the Marijuana Industry
- Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) All Indications Point to Billion Dollar CBD Markets Should Continue to Skyrocket
- Green Hygienics Holdings Inc. (GRYN) University of Wyoming Releases Hemp Publication
- Hemptown USA - Advances Growth Strategy via Nutraceutical Manufacturing Facility Acquisition
- HTC Extraction Systems (TSX.V: HTC) Market Data Hints at Excellent Opportunities for Hemp Biomass Companies Like HTC Extraction Systems
- INmune Bio, Inc. (NASDAQ: INMB) to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
- IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) Addresses Concerns about Vape Safety, Calls for Stricter Regulation of Black Market
- Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Provides Update on R&D Program Progress under License Agreement with Altria
- Marijuana Company of America Inc. (MCOA) Global CBD Prices Reduce as US Supply Shakes the Market
- MustGrow Biologics Corp (CSE: MGRO) Outlines Portfolio of Natural Bio-Pesticides and Bio-Fertility Products
- Neutra Corp. (OTCQB: NTRR) California Cities and Counties Still Divided on Hemp Cultivation
- Nightfood, Inc. (OTCQB: NGTF) Announces Distribution in Harris Teeter Supermarkets, Adding Over 250 Stores Throughout the Southeast and Mid-Atlantic Regions
- Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) These are the Biggest Catalysts for CBD in 2020
- ORHub Inc. (ORHB) Settles Litigation with Former Chief Financial Officer
- Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) Ongoing Drill Results Confirm Significant, Near Surface Cobalt and Nickel Mineralization
- Pacific Software, Inc. (PFSF) Collaborates with Império for Commercial Marketing and Promotion of BOAPIN.com Trade Portal
- Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Resumes Clean Oil Recovery Technology (CORT) Extraction Following Facility Upgrades
- Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) Announces Launch of Edibles Products into Nevada Adult-Use Cannabis Market
- Predictive Oncology Inc. (NASDAQ: POAI) Continues to Innovate to Improve Outcomes for Cancer Patients
- Pressure BioSciences Inc. (PBIO) Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.
- Quest Patent Research Corp. (QPRC) Holds Broad Portfolio of Intellectual Property Assets
- Sharing Services Global Corporation (SHRG) Offers Independence, Flexibility and Happiness
- SinglePoint, Inc. (SING) Australian Trial Shows CBD Gel Reduces Seizures in Epileptic Kids
- Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Announces Leading Taxi Technology Distributor Increases Purchase Order to Over $850,000
- Spectrum Global Solutions, Inc. (SGSI) Secures $3.3 Million in New Contract Awards
- Sproutly Canada, Inc. (OTC: SRUTF) (CSE: SPR) (FRA: 38G) Provides Business Update on the Moosehead Joint Venture for Cannabis Beverages
- SRAX Inc. (NASDAQ: SRAX) Showcases Company Presentation at Leading Consumer & Media Conference, Reviews Impressive Growth
- Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF) CEO to Participate at September 17 Battery Next Summit in Boulder, CO
- Sugarmade, Inc. (SGMD) 420 with CNW – 5 Things to Discuss about Medical Marijuana with Your Doctor
- The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Blissco Wellness Brand Receives Cannabis Oil Sales License
- The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) 420 with CNW – Another Marijuana Legalization Bill Introduced in Mexico Legislature
- Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Australian Trial Shows CBD Gel Reduces Seizures in Epileptic Kids
- Trxade Group Inc. (TRXD) Empowers Small, Independent Pharmacies
- VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) Reaffirms Timing of First Harvest at Kimmetts and Additional 2020 Cultivation Plans
- VPR Brands, LP (VPRB) Offers Robust Suite of Products in Nicotine, CBD Verticals
- Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) New Study Finds Florida Residents Among the Heaviest of CBD Users
- Willow Biosciences Inc. (CSE: WLLW) New Study Finds Florida Residents Among the Heaviest of CBD Users
- Xalles Holdings Inc. (XALL) Building Fintech Support Strategy Through Acquisitions, Mentoring
- Youngevity International, Inc. (NASDAQ: YGYI) Announces Dividend Payment Timing for September 2019 Series “D” Cumulative Redeemable Perpetual Preferred Stock
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.